Journal: Scientific Reports

Article Title: Melatonin suppresses PD-L1 expression and exerts antitumor activity in hepatocellular carcinoma

doi: 10.1038/s41598-025-93486-4

Figure Lengend Snippet:

Article Snippet: PD-L1 , Abclonal , A1645.

Techniques:

Journal: Frontiers in Immunology

Article Title: Ginsenoside Rg3 targets glycosylation of PD-L1 to enhance anti-tumor immunity in non-small cell lung cancer

doi: 10.3389/fimmu.2024.1434078

Figure Lengend Snippet: PD-L1 is highly glycosylated in NSCLC cells. (A) Western blot analysis of PD-L1 expression in H1975, H1299, A549 and HCC827 cells. Red asterisk indicated the glycosylated form of PD-L1. (B) H1975 cells were treated with either 5 μg/mL tunicamycin or 20 μM OSMI-4 for 24 h. The expression of PD-L1 was analyzed by western blot. (C) H1975 cells were treated with either 5 μg/mL tunicamycin or 20 μM OSMI-4 for 24 h. Cell viability was determined (n=3). Data were shown as mean ± SD. n.s., not significant.

Article Snippet: The primary antibodies used were as follows: EGFR (Cat No. A23381, 1:1000, Abclonal), Phospho-EGFR-Y1068(Cat No. AP0301, 1:1000, Abclonal), GSK3β (Cat No.9315, 1:1000, Cell Signaling Technology), phospho-GSK3β Ser9 (Cat No.9336, 1:1000, Cell Signaling Technology), PD-L1 (Cat No. A1645, 1:1000, Abclonal) and β-actin (Cat No. AC038, 1:5000, Abclonal).

Techniques: Western Blot, Expressing

Journal: Frontiers in Immunology

Article Title: Ginsenoside Rg3 targets glycosylation of PD-L1 to enhance anti-tumor immunity in non-small cell lung cancer

doi: 10.3389/fimmu.2024.1434078

Figure Lengend Snippet: Ginsenoside Rg3 attenuates the glycosylation of PD-L1 through inhibiting EGFR signaling. (A) Cell viability (n=3). (B) Relative expression of CD274 after 24 h of Rg3 treatments at indicated concentration (n=3). (C) H1975 cells were treated with 10 ng/mL IFN-γ with or without 50 μM Rg3. The percentage of PD-L1 + cells was determined by flow cytometry. (D) Quantification of PD-L1 + cells (n=3). (E–H) H1975 cells were treated with 25 μM or 50 μM Rg3 for 24 h. The expression of p-EGFR, EGFR, p-GSK3β, GSK3β and PD-L1 were determined by western blot. Quantified results were shown. Data were shown as mean ± SD. * p < 0.05, *** p < 0.001 compared to vehicle group. n.s., not significant.

Article Snippet: The primary antibodies used were as follows: EGFR (Cat No. A23381, 1:1000, Abclonal), Phospho-EGFR-Y1068(Cat No. AP0301, 1:1000, Abclonal), GSK3β (Cat No.9315, 1:1000, Cell Signaling Technology), phospho-GSK3β Ser9 (Cat No.9336, 1:1000, Cell Signaling Technology), PD-L1 (Cat No. A1645, 1:1000, Abclonal) and β-actin (Cat No. AC038, 1:5000, Abclonal).

Techniques: Glycoproteomics, Expressing, Concentration Assay, Flow Cytometry, Western Blot

Journal: Frontiers in Immunology

Article Title: Ginsenoside Rg3 targets glycosylation of PD-L1 to enhance anti-tumor immunity in non-small cell lung cancer

doi: 10.3389/fimmu.2024.1434078

Figure Lengend Snippet: Inhibition of PD-L1 glycosylation enhances T cell mediated tumor cell killing in vitro . (A) Schematic illustration of coculture experiment. (B) Percentage of 7-AAD + cells in CD3 - cells (n=3). (C) Histogram of CD25 after coculture and Rg3 treatment. (D) Percentage of CD25 + CD3 + cells in each group (n=3). (E–G) Concentration of IL-2 (E) , IFN-γ (F) and TNF-α (G) in cell culture supernatant (n=3). Data were shown as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001. n.s., not significant.

Article Snippet: The primary antibodies used were as follows: EGFR (Cat No. A23381, 1:1000, Abclonal), Phospho-EGFR-Y1068(Cat No. AP0301, 1:1000, Abclonal), GSK3β (Cat No.9315, 1:1000, Cell Signaling Technology), phospho-GSK3β Ser9 (Cat No.9336, 1:1000, Cell Signaling Technology), PD-L1 (Cat No. A1645, 1:1000, Abclonal) and β-actin (Cat No. AC038, 1:5000, Abclonal).

Techniques: Inhibition, Glycoproteomics, In Vitro, Concentration Assay, Cell Culture

Journal: Frontiers in Immunology

Article Title: Ginsenoside Rg3 targets glycosylation of PD-L1 to enhance anti-tumor immunity in non-small cell lung cancer

doi: 10.3389/fimmu.2024.1434078

Figure Lengend Snippet: Ginsenoside Rg3 attenuated PD-L1 glycosylation and restored anti-tumor immunity. (A) Western blot analysis of PD-L1 in tumor tissues. Red asterisk indicated the glycosylated form of PD-L1. (B) Relative PD-L1 protein expression (n=3). (C–F) Flow cytometry analysis of GzmB + (C, E) and Perforin + (D, F) CD8 + T cells in tumor microenvironment (n=5). (G) Percentage of CD4 + T cells in tumor microenvironment (n=5). (H) Percentage of CD8 + T cells in tumor microenvironment (n=5). Data were shown as mean ± SD. * p < 0.05, ** p < 0.01 compared to model group.

Article Snippet: The primary antibodies used were as follows: EGFR (Cat No. A23381, 1:1000, Abclonal), Phospho-EGFR-Y1068(Cat No. AP0301, 1:1000, Abclonal), GSK3β (Cat No.9315, 1:1000, Cell Signaling Technology), phospho-GSK3β Ser9 (Cat No.9336, 1:1000, Cell Signaling Technology), PD-L1 (Cat No. A1645, 1:1000, Abclonal) and β-actin (Cat No. AC038, 1:5000, Abclonal).

Techniques: Glycoproteomics, Western Blot, Expressing, Flow Cytometry